Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) (TA965)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 March 2024
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s (NG202)Product type:GuidanceProgramme:NICE guidelinePublished: 20 August 2021
Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)Product type:GuidanceProgramme:NICE guidelineLast updated: 26 July 2019Published: 5 December 2018
Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing (NG114)Product type:GuidanceProgramme:NICE guidelinePublished: 5 December 2018
Roflumilast for treating chronic obstructive pulmonary disease (TA461)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 July 2017
FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome (MIB281)Product type:AdviceProgramme:Medtech innovation briefingPublished: 7 December 2021
Artificial intelligence for analysing chest CT images (MIB243)Product type:AdviceProgramme:Medtech innovation briefingPublished: 5 January 2021
myAIRVO2 for the treatment of chronic obstructive pulmonary disease (MIB161)Product type:AdviceProgramme:Medtech innovation briefingPublished: 1 October 2018
OxyMask for delivering oxygen therapy (MIB160)Product type:AdviceProgramme:Medtech innovation briefingPublished: 27 September 2018
VIDAvision for lung volume analysis in emphysema (MIB148)Product type:AdviceProgramme:Medtech innovation briefingPublished: 5 June 2018
Chronic obstructive pulmonary disease in adults (QS10)Product type:Quality standardLast updated: 19 September 2023Published: 28 July 2011
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [ID6235]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 5 March 2026
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID1237Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 6 August 2026
Balloon dilation plus spiculiform electrosurgery towards the therapy of obstructive Airway Disease: Central Airway Fibrotic Stricture - benignStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Use of a glue or sealant to achieve lung volume reduction in emphysema and lung cancerStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Bronchoscopic intrabullous autologous blood instillation (BIABI) for the therapy of Emphysema: intractable with pneumothorax, COPD & Lung cancer, patients requiring lung biopsyStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
MT633 FreeO2 Automatic Oxygen TitrationStatus:Topic prioritisationProgramme:Medical technologies guidanceExpected publication date: TBC
RespiraSense (MT736)Status:Topic prioritisationProgramme:Medical technologies guidanceExpected publication date: TBC
Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mepolizumab for treating chronic obstructive pulmonary disease with eosinophil-associated exacerbations TSID12019Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tozorakimab for treating exacerbations of chronic obstructive pulmonary disease after optimised inhaled dual or triple therapy [TSID12344]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC